nsclc with egfr exon 20 shows benefit with mobocertinib over chemotherapy
Published 4 years ago • 395 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:32
real-world comparison assesses mobocertinib in nsclc with egfr exon 20
-
32:15
a visual exploration of new targeted therapies for egfr exon 20 insertions in nsclc
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
4:47
treating non–small cell lung cancer with an egfr exon 20 insertion
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
6:07
amivantamab and mobocertinib for egfr exon-20 disease - lung cancer video library
-
16:16
managing patients with egfr exon 20 ins in nsclc and egfr tki toxicity
-
5:46
lung cancer video library 2020 - patel emerging molecular targets in nsclc egfr exon 20
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc
-
0:53
treatments for patients with nsclc carrying egfr exon 20 insertions
-
27:17
real world data and diagnostics in patients with nsclc with egfr exon 20 insertions
-
0:52
targeted treatments for egfr exon 20 insertion mutations in nsclc
-
37:32
latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and impli...
-
6:57
egfr exon 20 mutations in non–small cell lung cancer
-
4:27
amivantamab shows robust efficacy in post-platinum therapy patients with egfr ex20ins nsclc
-
5:50
targeted therapy in egfr exon 20-mutant non–small cell lung cancer
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
1:07
dr. horn on the role of mobocertinib in nsclc
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc